Alkermes plc. Files 8-K on Nov 12, 2025

Ticker: ALKS · Form: 8-K · Filed: 2025-11-12T00:00:00.000Z

Sentiment: neutral

Topics: corporate-disclosure, financial-reporting

TL;DR

Alkermes dropped an 8-K on 11/12/25 covering Reg FD, other events, and financials.

AI Summary

Alkermes plc. filed an 8-K on November 12, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company, formerly known as Antler Science Two PLC, is incorporated in Ireland and its principal executive offices are located in Dublin.

Why It Matters

This 8-K filing provides updates on Alkermes' corporate activities and financial reporting, which are important for investors to monitor the company's status and compliance.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain any immediate material risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Alkermes plc.?

The primary purpose is to report on various events including Regulation FD disclosures, other events, and financial statements and exhibits, as of November 12, 2025.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on November 12, 2025.

What was Alkermes plc. formerly known as?

Alkermes plc. was formerly known as Antler Science Two PLC.

In which jurisdiction is Alkermes plc. incorporated?

Alkermes plc. is incorporated in Ireland.

Where are Alkermes plc.'s principal executive offices located?

Alkermes plc.'s principal executive offices are located at Connaught House, 1 Burlington Road, Dublin 4, Ireland.

Filing Stats: 615 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-11-12 08:45:28

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On November 12, 2025, Alkermes plc (the "Company") issued a press release regarding the positive topline results described in Item 8.01 of this Current Report on Form 8-K. A copy of the press release containing a summary of the topline results is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 7.01, and in Exhibit 99.1 furnished herewith, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On November 12, 2025, the Company announced positive topline results from the randomized, double-blind treatment period of Vibrance-2, a phase 2 study evaluating the safety and efficacy of alixorexton (formerly referred to as ALKS 2680) compared to placebo in patients with narcolepsy type 2. Alkermes hosted an investor webcast and conference call to present the topline results. A copy of the presentation displayed during the webcast and conference call detailing the topline results is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

01 Financial Sta tements and Exhibits

Item 9.01 Financial Sta tements and Exhibits. (d) Exhibits EXHIBIT INDEX Exhibit No. Description 99.1 Press release issued by Alkermes plc dated November 12, 2025. 99.2 Investor presentation of Alkermes plc displayed on November 12, 2025. 104 Cover page interactive data file (embedded within the Inline XBRL document). 2 SIGNA TURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALKERMES PLC Date: November 12, 2025 By: /s/ David J. Gaffin David J. Gaffin Secretary 3

View on Read The Filing